Wed.Jun 12, 2024

article thumbnail

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

Bio Pharma Dive

Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

Drugs 287
article thumbnail

Data sharing will be key in repairing the UK clinical ecosystem

Pharmaceutical Technology

Lord James O'Shaughnessy, the former health minister, outlines places where the UK is falling behind other countries with clinical research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regenxbio CEO to step down after 15 years

Bio Pharma Dive

Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

article thumbnail

Siegfried to boost drug substances offering with new acquisition

Pharmaceutical Technology

Siegfried has announced the signing of binding agreements with Curia Global to acquire an early-phase CDMO site in Grafton, Wisconsin, US.

Drugs 203
article thumbnail

How to Turn “Check-the-Box” Compliance Trainings Into Real Learning

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.

article thumbnail

Ultragenyx, Mereo drug reduces fractures in bone disorder study

Bio Pharma Dive

New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.

Drugs 205
article thumbnail

Anti-obesity drugs will be 2024’s defining trend

Pharmaceutical Technology

GlobalData’s newest update notes the impact of the growing anti-obesity market, apersonalised medicines, real-world evidence, and cell and gene therapies.

More Trending

article thumbnail

New study reveals how brain cell communication is linked to Alzheimer’s disease

Pharma Times

Two support cells, microglia and astrocytes, were found to communicate with each other

Research 172
article thumbnail

Flagship taps startup to hunt for obesity drugs that might interest Pfizer

Bio Pharma Dive

The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

Drugs 184
article thumbnail

Merck KGaA invests in Life Science business facility in Germany

Pharmaceutical Technology

Merck KGaA announced a €62m ($66.

article thumbnail

ICL receives £10m donation to advance heart and lung research

Pharma Times

The donation will help scientists and clinicians collaborate and make new advances in research

Research 153
article thumbnail

Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

article thumbnail

June 12, 2024: Registry-Based DAPA-MI Trial to Be Featured in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

Dr. Stefan James and Dr. Jonas Oldgren In this Friday’s PCT Grand Rounds, Stefan James and Jonas Oldgren of Uppsala University will present “DAPA-MI – A Pragmatic Registry-Based Double-Blind RCT Trial Designed for Regulatory Evaluation.” The Grand Rounds session will be held on Friday, June 14, 2024, at 1:00 pm eastern. DAPA-MI (Dapagliflozin in Patients With MI) was a registry-based, placebo-controlled trial of dapagliflozin in patients hospitalized for myocardial infarction a

Trials 147
article thumbnail

Bankrupt Mithra cashes in on remaining assets for $188.2m

Pharmaceutical Technology

Gedeon Richter gains rights to Mithra’s estetrol range in addition to subsidiaries Neuralis and Estetra.

130
130
article thumbnail

BMS chief Boerner says company is still hungry for deals after spending more than $20B on M&A last year

Fierce Pharma

As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target | As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target comes along.

119
119
article thumbnail

Thinking outside of the box: Digitising pharmacy dispensing labels

Pharmaceutical Technology

Written Medicine is a digital solution that provides bilingual dispensing labels, described in a presentation at the NHS ConfedExpo conference in Manchester.

Pharmacy 130
article thumbnail

Can Your Organization Spot a Conflict Before It’s a Crisis?

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

article thumbnail

OTC Hearing Aids: “Nothing to See Here” Says GAO Report

FDA Law Blog

By Sara W. Koblitz & Jeffrey N. Gibbs — It’s been over a year and a half since Over-the-Counter (“OTC”) hearing aids became legal, and it’s not clear that they’ve made the difference in hearing loss treatment that Congress anticipated. (FDA once estimated that OTC hearing aids would save patients over $3000.) A recent GAO Report hasn’t found that OTC hearing aids have had much impact.

article thumbnail

Study finds most patients in TARGET-NASH registry meet revised MASLD criteria

Pharmaceutical Technology

In 2023, MASLD replaced the umbrella term of nonalcoholic fatty liver disease (NAFLD) to avoid the potentially stigmatising language of the former name.

130
130
article thumbnail

NICE declines to look again at depression drug Spravato

pharmaphorum

Johnson & Johnson has slammed a decision by NICE not to carry out a new appraisal of its antidepressant Spravato, claiming it has “grave concern” about access to new mental health treatments through NHS England.

Drugs 108
article thumbnail

Syntis Bio launches oral therapies for metabolic diseases

Pharmaceutical Technology

Syntis Bio is to develop oral therapies targeting a range of metabolic diseases, from obesity to rare conditions.

article thumbnail

White Paper - A Roadmap to AI Data Readiness in R&D Labs

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

article thumbnail

Amid FTC crackdown, judge says Teva inhaler patents are 'improperly listed' in FDA Orange Book

Fierce Pharma

After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade Commission’s (FTC’s) ongoing crusade against questionable drug patents. | A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book.

Drugs 108
article thumbnail

Cyrus Biotechnology to spin out Levitate Bio for biopharma AI

Pharmaceutical Technology

Software-enabled biotechnology company Cyrus Biotechnology has announced the spinout of Levitate Bio to enhance biopharma AI offerings.

130
130
article thumbnail

How long does a patent last for drugs?

Drug Patent Watch

Sure, here’s a more detailed explanation with examples: Drug Patent Duration Drug patents are granted by the United States Patent and Trademark Office (USPTO) for a period of 20 years… Source

Drugs 107
article thumbnail

South Korea and Australia on the rise as clinical research hubs

Pharmaceutical Technology

Novotech’s vice president highlighted the APAC region’s growing clinical presence, drawing attention to Australia and South Korea.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Pharma Pulse 6/12/24: The Healthcare System is Changing—So How Should We Respond?, What the Apple-OpenAI Deal Means for Four Tech Titans & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

The 6 Largest Biopharma Layoffs of 2024 So Far

BioSpace

Despite a surge in the financial markets, multiple Big Pharma companies have announced hundreds or even thousands of cuts. Experts hope for a better second half of the year.

article thumbnail

Junshi, Coherus' PD-1 inhibitor Loqtorzi scores in phase 3 liver cancer trial

Fierce Pharma

Junshi revealed that a phase 3 trial of Loqtorzi plus Avastin prolonged the survival of first-line patients with hepatocellular carcinoma.

Trials 98
article thumbnail

Insights into Precision Dosing with Dr. Howard McLeod and Dr. Sharmeen Roy – Xtalks Life Science Podcast Ep. 163

XTalks

In this episode, Ayesha spoke with Howard McLeod, PharmD , Director of the Center for Precision Medicine and Functional Genomics, Professor of Pharmacy and Medicine at Utah Tech University and Precision Medicine Advisor at the Geriatric Oncology Consortium; and Sharmeen Roy, PharmD, Chief Strategy and Science Officer at DoseMe , which is the world’s first and largest Bayesian dosing platform designed for clinical practice.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Secondary Cancer Risk Is Low After CAR-T Cell Treatment: Stanford Study

BioSpace

Results of a large Stanford Medicine study, published Wednesday in The New England Journal of Medicine, finds CAR-T therapies carry a low risk of secondary malignancies not related to the CAR-T cells.

article thumbnail

The Rise of Specialty Benefit Managers: What Pharma Should Know

Fierce Pharma

By Steve Callahan, Director, Advisory & Insights, MMIT | New research shows that many payers are relying heavily on third-party specialty benefit managers to reduce costs across multiple therapeutic areas.

article thumbnail

Pfizer, Flagship Pioneering to Target Obesity Treatments Under 2023 Partnership

BioSpace

Building on last year’s potential $7 billion partnership with Flagship Pioneering, Pfizer and Flagship-founded ProFound Therapeutics will work on discovering new obesity candidates.

92
article thumbnail

The Rise of Hard Ice Cream: PROOF Hard Ice Cream’s Debut

XTalks

Hard ice cream, a fusion of creamy dessert and spirited indulgence, is gaining traction in the food industry. A leader in the space, PROOF Hard Ice Cream , is set to make a splash this summer at Summerfest 2024, one of the nation’s largest outdoor music festivals. This June and July, PROOF Hard Ice Cream will captivate Summerfest attendees with its unique offerings.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model